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 SHORT REPORT
Genetic epilepsy with febrile seizures plus: definite
and borderline phenotypes
R H Thomas,1,2,3 J A Johnston,1,2,3 C L Hammond,1,3,4 S Bagguley,2 C White,3,5
P E Smith,2,3 M I Rees1,3
ABSTRACT
Generalised epilepsy with febrile seizures plus (GEFS+) is
the most studied familial epilepsy syndrome. However,
characteristics of UK families have not previously been
reported. Among the first 80 families recruited to our
families study, four broad subphenotypes were identified:
families with classical GEFS+; families with borderline
GEFS+; families with unclassified epilepsy; and families
with an alternative syndromal diagnosis. Borderline GEFS+
families shared many characteristics of classical GEFS+
familiesdsuch as prominent febrile seizures plus and early
onset febrile seizuresdbut included more adults with focal
epilepsies (rather than the idiopathic generalised epilepsies
predominating in GEFS+) and double the prevalence of
migraine. Thus the authors believe that a novel and robust
familial epilepsy phenotype has been identified.
Subcategorising families with epilepsy is helpful in
targeting both clinical and research resources. Most
families with GEFS+ have no identified causal mutation,
and so predicting genetic homogeneity by identifying
endophenotypes becomes more important.
INTRODUCTION
Generalised epilepsy with febrile seizures plus
(GEFS+) was ﬁrst proposed as a diagnostic entity
in 1997.1 The families broadly have idiopathic
generalised epilepsy but with a predominance of
febrile and febrile seizures plus (FS+); indeed, FS
are considered the prototype seizure in GEFS+.
Additionally, young children with catastrophic
epilepsy syndromes (such as severe myoclonic
epilepsy of infancy (SMEI)) occur more frequently
among GEFS+ families than expected by chance.
Family members with speciﬁc electroclinical
syndromes (such as childhood absence epilepsy or
juvenile myoclonic epilepsy) would be unusual but
are seen infrequently. However, the occurrence of
occasional family members with focal epilepsies has
led to the suggestion that the GEFS+ acronym
better describes genetic epilepsy with FS+. GEFS+
is now widely recognised and is a core diagnosis
seen in studies of families with epilepsy.
Berkovic and Sheffer ’s original GEFS+ descrip-
tion deﬁned a GEFS+ ‘spectrum’, ranging from
individuals with simple FS and FS+ up to SMEI.
The generalised epilepsy phenotypes included
absence seizures, myoclonic seizures and, more
rarely, atonic and myocloniceastatic seizures. It
was also suggested that the pedigree showed an
autosomal dominant pattern with incomplete
penetrance.1 The gene mutations thus far described
in association with GEFS+ have coded for ion
channels: private mutations in SCN1A, SCN1B and
GABRG2 genes occur in 10% of families with the
GEFS+ phenotype.2 3 Although the genetic causes
of most epilepsies (including GEFS+) have yet to be
elucidated, it is still widely believed that most
epilepsies have some genetic component.4 Siblings
of an individual with conﬁrmed seizures have an
approximately ﬁvefold risk of developing epilepsy
(compared with a background risk of 0.75%),
depending on the age of onset of the seizures. A
monozygotic twin with an affected twin has
between 37% and 80% risk of developing epilepsy,
compared with between 3% and 32% for a dizy-
gotic twin.5 This also implies an environmental
aspect to the aetiology; in the case of GEFS+, this
may be the infantile illness needed to provoke
typical and FS+. Mutations in the sodium channel
may also lead to an increased risk of febrile
convulsions which itself increases the risk of
developing epilepsy.6 This would certainly seem
logical, as sodium channel defects are known to
causes disorders inﬂuenced by temperature, such as
paramyotonia congenita.7
More than 600 SCN1A mutations have been
described,8 9 missense mutations being the most
frequent. Frameshift and nonsense mutations are
associated with the more deleterious epilepsies, such
as SMEI.2 3 10 The mutations are spread throughout
the gene but occur most frequently outside the pore
forming region.11 12 Initially, the GEFS+ family
phenotype was tightly deﬁned but the borders of
both epilepsy within GEFS+ families and the
epilepsy caused by SCN1A mutations are increas-
ingly blurred. GEFS+ families from the UK have not
been previously systematically described and
analysed, despite the original family described being
Anglo-Australian.1 We present our experience and
the clinical description of our GEFS+ families.
METHODS
Eighty families were consented and recruited for
future genetic analysis (MREC approval 05/
MRE09/78). Families were referred by epilepsy
clinicians or self-referred following advertisements
placed in epilepsy charity magazines. All available
family members were interviewed by neurologists
with clinical experience of epilepsy (JAJ, RHT).
The characteristics of individuals were ascertained
via semistructured interview and the pedigrees
charted. Focused comorbidity data were collected,
including conditions with a presumed channelop-
athy basis (migraine) and conditions associated
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with increased frequency of microdeletions and insertions
(learning difﬁculties). Consensus as to whether the families met
the original (1997) criteria for GEFS+ was achieved following
debate within a team comprising two clinical research fellows,
a professor of molecular genetics, a paediatric neurologist and
a genetic counsellor. Families were divided into four groups:
classical GEFS+, borderline GEFS+, unlikely to be GEFS+
(broadly unclassiﬁed epilepsies) and those with another speciﬁc
familial epilepsy syndrome. The characteristics of the individ-
uals with epilepsy from within these families were extracted for
analysis and the c2 test (with Yates’ correction when needed)
was used. People were identiﬁed as having FS (simple FS), FS+
(generalised or partial seizures that continue to occur after the
age of 5 years, or in the absence of a very high temperature),1
generalised toniceclonic seizures (GTCS) as an adult (beyond
age 18 years) or other types of seizures. Focal epilepsy
syndromes were conﬁrmed by reviewing clinic letters.
RESULTS
Characteristics of the families
Of the ﬁrst 80 families, 29 were recruited via neurologists, 19 by
paediatricians and 17 were self-referrals, seven from epilepsy
nurse specialists, four through clinical databases, three from the
learning disability service and one from clinical genetics. Four-
teen families were classiﬁed as classical GEFS+ and 10 as
borderline (ﬁgure 1). In eight families, GEFS+ was considered
unlikely and the epilepsy phenotype was unclassiﬁable; 48 had
another speciﬁc syndromal diagnosis. Borderline GEFS+ families
had a greater mix of epilepsy diagnoses (including electroclinical
syndromes, such as juvenile myoclonic epilepsy, and focal
epilepsies, such as temporal lobe epilepsy) than those with
deﬁnite GEFS+. Idiopathic generalised epilepsy comprised 80%
of diagnoses that persisted into adulthood in deﬁnite GEFS+ but
only 60% for borderline families (p<0.01), where there were
twice as many adults with focal epilepsies.
Individual characteristics
Classical GEFS+ familiesd120 individuals had seizures: 77 had
FS (64.2%) and of these, seven also had afebrile seizures (AFS)
(5.8%) and 18 later had adult GTCS (1.5%); 23 had AFS (19.2%)
with ﬁve later going on to have adult GTCS (4.2%); 22.5% (27
people) had adult GTCS with no preceding febrile seizures.
Borderline GEFS+ familiesd83 people reported seizures: 43 had
FS (51.8%), three with both FS and AFS (3.6%) and nine later
having adult GTCS (10.8%); 11 people had AFS (13.3%), three of
whom later developed GTCS (3.6%); 27 people (32.5%) had
adult onset GTCS only.
Unclassiﬁed familial epilepsyd80 had seizures or epilepsy: 20 had
FS (25%), three of whom (3.8%) had both FS and AFS and ﬁve
later had adult GTCS (6.3%); 13 had AFS (16.25%), four of
whom (5%) later had adult GTCS; 45 (56.3%) had adult GTCS
only.
FS were reported twice as often in classical GEFS+ or borderline
GEFS+ families (p<0.005) than in those with unclassiﬁed
epilepsies. FS+ were rare but occurred disproportionately in
classical and borderline GEFS+ families, accounting for 24% and
19% of febrile seizures, respectively. There was also a trend
towards typical FS occurring earlier in GEFS+ families. No
family included any member with SMEI or a similar epileptic
encephalopathy. Thirty-ﬁve people had learning difﬁculties (33
having a clinical diagnosis of epilepsy); there was no increased
likelihood of learning difﬁculty across any of the four diagnostic
groups. The prevalence of migraine was 12%, similar to the
population estimate. However, migraine prevalence was signiﬁ-
cantly higher in the borderline GEFS+ group, with 25% of those
with epilepsy also having migraine. The migraine prevalence in
the classical GEFS+ group was 8.2% (classical vs borderline
groups, p<0.01) and was 7.1% in the unlikely GEFS+ group
(borderline vs unclassiﬁed, p<0.03). The migraine described was
mostly without aura, but migraine with aura and, rarely,
hemiplegic migraine were also seen.
DISCUSSION
We have reported a novel epilepsy familial subphenotyped
borderline GEFS+. It is likely to be a polygenic epilepsy
syndrome sharing many, but not all, points of variation with
classical GEFS+. The Wales Epilepsy Research Network clas-
siﬁcation (table 1) has features which may help focus gene
screening projects. We recognise some limitations to this type
of work. Not every individual had an EEG and, although where
possible we corroborated the stories given with medical
records, it is likely that there was a degree of non-disclosure in
all of the families studied. However, we believe that identifying
the concept of borderline GEFS+ and its relationship with
migraine (also believed to be a channelopathy) may help to
explain their shared pathogenesis.13 Recently, a dominant
negative mutation in the TRESK potassium channel has been
identiﬁed in a family with migraine with aura.14 The frame-
shift mutation in the KCNK18 gene renders the channel non-
functional and may offer a therapeutic target. Antiepileptic
drugs such as topiramate and sodium valproate are commonly
used as secondline agents for migraine prophylaxis; indeed, the
novel antiepilepsy agent retigabine is thought to act at the
KCNQ/Kv7 potassium channel.15 The concept of a genetically
homogenous GEFS+ syndrome is difﬁcult to support by
intrafamilial heterogeneity, even within the subcategories
Figure 1 Generalised epilepsy with febrile seizures plus (GEFS+) and
borderline GEFS+ pedigrees. Pedigree A, GEFS+; pedigrees B and C,
borderline GEFS+. Febrile seizures (top left quadrant black), afebrile
seizures (bottom left quadrant grey), generalised toniceclonic seizures
as an adult (shaded symbol), migraine (central circle), learning
difficulties (top right quadrant grey).
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proposed; borderline GEFS+ families had twice the number of
adults with a symptomatic focal epilepsy (40% vs 20%) than
those seen in classical GEFS+.
Febrile seizures
The most common seizure phenotype in UK GEFS+ families
was the FS, occurring in over half of the individuals among
classical or borderline GEFS+ families. Most did not progress to
either further generalised seizures or to an adult epilepsy
pattern. FS are notoriously under-reported by older relatives,16
potentially artiﬁcially reducing their prevalence. Fifty per cent of
the people who had seizures from classical or borderline GEFS+
families experienced generalised seizures (compared with
33e67% in the original Australian families).1 FS+ were rare, and
were speciﬁc (97.5%) but not sensitive for identifying GEFS+ or
GEFS+ borderline families, accounting for 24% and 19% of FS,
respectively. In the families with borderline GEFS+, median age
of onset of FS was 12 months. This is similar to the reported
median age of onset ranging between 11 and 12 months in
individuals with SCN1Amutations17 but earlier than the general
population average of 18 months.
CONCLUSION
We have identiﬁed a novel familial subphenotype within this UK
based cohortdborderline GEFS+dand have suggested criteria
for identifying these families. Borderline GEFS+ families have
prominent FS+ but twice the migraine prevalence of other
familial epilepsy and a greater preponderance of adults with
symptomatic epilepsies. Identifying families with either a classic
or borderline phenotype will be important for efﬁcient direction
of resources to inform gene discovery.
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Table 1 Wales Epilepsy Research Network criteria for definite and
borderline generalised epilepsy with febrile seizures plus
Classical Borderline Unclassified
Other
diagnoses
FS Y Y Y Y/N
FS+ Y Y Y /N N
Adult
epilepsydIGE
++ + +/ +/
Characteristic
seizure type
FS+ FS+ GTCS without
prior FS
Migraine + ++ + +
Electroclinical
syndromes
+/ + + ++
Most common
seizure type
FS FS GTCS Other
The characteristic seizure type is the most distinctive event that may help differentiate
the subtype, whereupon the most common seizure is the most frequently occurring.
FS, febrile seizures; FS+, febrile seizures plus; GEFS+, generalised epilepsy with febrile
seizures plus; GTCS generalised toniceclonic seizures; IGE, idiopathic generalised epilepsy.
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